Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic factors in patients with advanced and recurrent colorectal cancer receiving last-line chemotherapy.

Die Pharmazie - 1 Feb 2018

Kimura M, Iwai M, Usami E, Teramachi H, Yoshimura T

Abstract excerpt

For patients with advanced/recurrent colorectal cancer, the trifluridine/tipiracil combination tablet (TAS 102) and regorafenib are last-line treatments. This study aimed to clarify prognostic factors in patients receiving last-line chemotherapy. Between April 2014 and December 2016, 47 patients received last-line chemotherapy at Ogaki Municipal Hospital, Japan. The primary outcome was overall survival. To...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics, Opioid
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Kaplan-Meier Estimate

Share to Neoplasm Recurrence, Local

Share to Proto-Oncogene Proteins p21(ras)

Share to Survival Analysis

Source

Identifiers

PMID: 29442015
DOI: 10.1691/ph.2018.7832

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic factors in patients with advanced and recurrent colorectal cancer receiving last-line chemotherapy.PMID 29442015Read ↗

Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumabSemantic proximity Read ↗

Association of RAS mutational status with clinical outcomes in metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib.Semantic proximity Read ↗

Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.Semantic proximity Read ↗

Regorafenib Therapy as a Third-Line Treatment for Metastatic Colorectal Cancer: A Single Center Long Term ExperienceSemantic proximity Read ↗

Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.Semantic proximity Read ↗

[Recent Advances in Systemic Chemotherapy for Metastatic Colorectal Cancer].Semantic proximity Read ↗

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.Semantic proximity Read ↗

Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.Semantic proximity Read ↗

A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.Semantic proximity Read ↗

Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment.Semantic proximity Read ↗

Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.Semantic proximity Read ↗

[Long-Term Survival of a Patient with KRAS Mutated Colon Cancer Successfully Treated with Regorafenib].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.